Downloaded on December  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43910

Research article

Activation of multiple signaling pathways 

causes developmental defects in mice with a 
Noonan syndrome–associated Sos1 mutation

Peng-Chieh Chen,1,2 Hiroko Wakimoto,1,3 David Conner,1 Toshiyuki Araki,4 Tao Yuan,2  

Amy Roberts,5 Christine E. Seidman,1,6 Roderick Bronson,7 Benjamin G. Neel,4  

Jonathan G. Seidman,1 and Raju Kucherlapati1,2

1Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA. 2Department of Medicine, Division of Genetics,  

Brigham and Women’s Hospital, Boston, Massachusetts, USA. 3Department of Cardiology, Children’s Hospital Boston, Boston, Massachusetts, USA.  
4Division of Stem Cells and Developmental Biology, Ontario Cancer Institute, University Health Network, Toronto, Canada. 5Children’s Hospital Boston,  

Boston, Massachusetts, USA. 6Howard Hughes Medical Institute, Boston, Massachusetts, USA. 7Rodent Histopathology Core,  

Harvard Medical School, Boston, Massachusetts, USA.

Noonan	syndrome	(NS)	is	an	autosomal	dominant	genetic	disorder	characterized	by	short	stature,	unique	
facial	features,	and	congenital	heart	disease.	About	10%–15%	of	individuals	with	NS	have	mutations	in	son	of	
sevenless	1	(SOS1),	which	encodes	a	RAS	and	RAC	guanine	nucleotide	exchange	factor	(GEF).	To	understand	
the	role	of	SOS1	in	the	pathogenesis	of	NS,	we	generated	mice	with	the	NS-associated	Sos1E846K	gain-of-
function	mutation.	Both	heterozygous	and	homozygous	mutant	mice	showed	many	NS-associated	pheno-
types,	including	growth	delay,	distinctive	facial	dysmorphia,	hematologic	abnormalities,	and	cardiac	defects.	
We	found	that	the	Ras/MAPK	pathway	as	well	as	Rac	and	Stat3	were	activated	in	the	mutant	hearts.	These	
data	provide	in	vivo	molecular	and	cellular	evidence	that	Sos1	is	a	GEF	for	Rac	under	physiological	condi-
tions	and	suggest	that	Rac	and	Stat3	activation	might	contribute	to	NS	phenotypes.	Furthermore,	prenatal	
administration	of	a	MEK	inhibitor	ameliorated	the	embryonic	lethality,	cardiac	defects,	and	NS	features	
of	the	homozygous	mutant	mice,	demonstrating	that	this	signaling	pathway	might	represent	a	promising	
therapeutic	target	for	NS.

Introduction
Noonan syndrome (NS), estimated to affect 1 out of 1,000–2,500 
newborns, is characterized by variable developmental delay, short 
stature, characteristic facial features, congenital heart disease 
(CHD), and predisposition to myeloproliferative disease (MPD) 
(1–4). CHD is the primary cause of morbidity and mortality in 
NS patients. Pulmonary valve stenosis (PS) is the most common  
NS-associated cardiac phenotype, although some NS patients have 
cardiac hypertrophy and/or septal defects.

NS can occur sporadically or be inherited in an autosomal domi-
nant fashion. Positional cloning and candidate gene approaches 
have identified NS-associated gene mutations in protein tyrosine 
phosphatase, non-receptor type 11 (PTPN11), son of sevenless 1 
(SOS1), and RAF1 in about 60%–70% of NS cases, along with more 
rare mutations in N-RAS, K-RAS, and SHOC2 (5–12). Although 
additional NS genes remain to be identified, all the NS genes iden-
tified thus far encode mutant versions of RAS/MAPK pathway 
components that result in increased signaling in the pathway. Sev-
eral related syndromes, also caused by mutations in RAS/MAPK 
family genes, share phenotypes with NS but also have significant 
differences (1). Although there is some purported genetic overlap, 
in most cases, mutations in different genes are associated with 
distinct syndromes. These disorders, now collectively referred to 
as the “Rasopathies,” show that germline mutations in members 
of the RAS/MAPK pathway lead to a phenotypically related set of 
genetic disorders (1, 13). A detailed understanding of the molecu-

Conflict	of	interest: The authors have declared that no conflict of interest exists.
Citation	for	this	article: J Clin Invest. 2010;120(12):4353–4365. doi:10.1172/JCI43910.

lar etiology of these syndromes should yield new insights into the 
complexity of RAS/MAPK pathway regulation and is critical to 
intelligent pharmacological intervention.

About 10%–15% of NS cases are caused by gain-of-function muta-
tions in SOS1 (7, 8), which encodes a bifunctional guanine nucleo-
tide exchange factor (GEF) for RAS and RAC (14–18). A common 
NS-associated SOS1 missense mutation, E846K, is thought to 
cause a conformational change in the protein that leads to consti-
tutive RASGEF activation (7, 8). Cultured cells transfected with the 
SOS1E846K mutant show sustained RAS activation and increased 
levels of phosphorylated ERK1/2 (p-ERK1/2) in response to EGF 
stimulation, suggesting that the RAS/MAPK pathway is activated  
by this mutation (8). Although most of the phenotypes in NS 
patients with the PTPN11 or SOS1 mutation are indistinguishable, 
PS and atrial septal defects (ASDs) are more prevalent in PTPN11 
cases than in SOS1 cases, whereas those with SOS1-associated NS 
are less likely to have short stature or significant developmental 
delays (7, 8), suggesting that the underlying molecular effects of 
SOS1 and PTPN11 mutations might be overlapping but distinct.

As  the  RAS/MAPK  pathway  is  also  frequently  affected  by 
mutations in cancers, many inhibitors of pathway components 
are under development as antineoplastic agents (19–21). These 
inhibitors might be useful for treating the Rasopathies. Accurate 
mouse models of these disorders can be useful for prioritizing 
potential therapeutic agents.

To better understand the molecular pathogenesis of NS caused 
by SOS1 mutations and to enable evaluation of drug interventions 
to treat the phenotypic features of NS, we generated and character-
ized a mouse line carrying the Sos1E846K-activating mutation.

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 12      December 2010 

4353

Downloaded on December  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43910

research article

Figure 1
Generation of knock-in mice expressing Sos1EK. (A) Schematic representation of unidirectional targeting of Sos1EK in exon 16. When Cre 
recombinase is present, inversions occur either between the wloxP sites or the mloxP sites at opposite orientations, generating loxP sites with 
identical orientation. Subsequently, Cre recombinase mediates the excision between wloxP or mloxP sites in the same orientation, resulting in 
a targeted exon bearing the E846K mutation (solid triangles, wloxP; open triangles, mloxP; ovals, FRT site). Exons are indicated by rectangles. 
Primer pairs indicated by red, blue, green, and purple arrows were used in long-range PCR to screen positive ES cell clones (see Methods and 
Supplemental Figure 6). (B) Results of PCR of 2 ES cell clones with (and 1 clone without) Ad-Cre infection, showing that the desired modification 
has been achieved, using primer pairs indicated by orange arrows in A. M, DNA marker. Numbers indicate the size of PCR bands in kilo-base 
pairs (kb). (C) Sos1EK activates Erk1/2 in 2 ES cell clones after Ad-Cre infection. ES cells were starved and stimulated with EGF (25 ng/ml) and 
analyzed by immunoblotting. (D) PCR results for genotyping the Sos1EK-targeted locus, using primer pairs indicated by brown arrows in A. (E) 
Sequencing results of the RT-PCR of WT and Sos1+/EK RNAs. The asterisk indicates the E846K mutation. (F) Immunoblotting showing equal 
amount of Sos1 proteins in tissues of all genotypes (1, WT; 2, Sos1+/EK; 3, Sos1EK/EK). (G) Kaplan-Meier survival curves of the mice. WT, n = 92; 
Sos1+/EK, n = 137; P = 0.02 versus WT. Sos1EK/EK, n = 4; P < 0.001 versus WT.

Results
Generation of E846K mice by unidirectional recombination. The MAPK 
pathway is critical for many cellular functions throughout embryo-
genesis. To eliminate the possibility that expression of an activat-
ing Sos1 mutation might lead to dominant embryonic lethality, we 
introduced a silent Sos1E846K mutation into mouse ES cells that 
could be activated only when desired. To accomplish this goal, we 
used a unidirectional loxP recombination system in which selective 
recombination is achieved by means of a mutant loxP (mloxP) site 
that preferentially recombines with another mloxP but not with 
WT loxP (wloxP) and vice versa (22) (Figure 1A).

To test the efficacy of this strategy, we infected properly targeted 
ES cells with Cre recombinase–encoding adenovirus (Ad-Cre). Exam-
ination of genomic DNA from resulting colonies using long-range 
PCR revealed the desired inversion and recombination events (Fig-
ure 1B). Importantly, the level of Sos1 protein in the infected colo-
nies was similar to that in the uninfected cells (Figure 1C). More-
over, p-Erk1/2 levels, an indicator of Erk activity, were increased in 

the infected cells in response to EGF stimulation (Figure 1C). These 
results indicated that the unidirectional recombination successfully 
introduced the functional E846K mutation into the ES cells.

We injected 2 ES clones (without Ad-Cre infection) into C57BL/6J  
blastocysts and obtained high-percentage chimeric mice that 
transmitted the modified allele to the germline. These mice were 
mated with EIIA-Cre transgenic mice, which express Cre recombi-
nase in their germline (23). Examination of DNA from the result-
ing mice using PCR and sequencing revealed that the recombina-
tion events occurred as expected (Figure 1D and data not shown). 
RT-PCR with mRNA-specific primers, followed by sequencing as 
well as immunoblotting experiments, showed that the Sos1E846K 
allele was expressed at normal levels (Figure 1, E and F). We refer 
to the mutant locus as Sos1EK.

Homozygosity of Sos1EK results in severe cardiac defects and embryonic  
lethality. We obtained Sos1+/EK mice at the expected Mendelian 
ratios from backcrosses with WT mice in a C57BL/6J background 
and from intercrosses of Sos1+/EK mice in a mixed C57BL/6J and 

4354	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 12      December 2010

Downloaded on December  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43910

research article

	

Genotype	

	

WT	(n)	

Sos1+/EK	(n)	

40 
4 
9 
12 
21 
45 
5 

45 
6 
15 
16 
33 
78 
22 

Sos1EK/EK	(n)	

– 

3 (+3) 
5 (+3) 
5 (+8) 
0 (+2) 

3 
9 

Deviation from the expected Mendelian frequency was assessed using the χ2 test. Numbers in parentheses indicate 
the number of degenerated embryos.

Table 1
Progeny from the indicated Sos1+/EK matings

Mice	

	
Sos1+/EK × WT 
Sos1+/EK × Sos1+/EK 
 
 
 
 
Sos1+/EK × Sos1+/EK  
  +PD0325901

Age	

	

3 weeks 
E10.5 
E13.5 
E15.5 
P0 

3 weeks 

P0 

129S1/SvImJ background (Table 1). However, the number of 
Sos1EK/EK progeny from the intercross was significantly lower than 
the expected frequency (n = 3 out of 126 mice, 2.38%; χ2 = 35.14,  
P < 0.0001; Table 1). Analysis of embryos at different stages of 
embryogenesis revealed that Sos1EK/EK mice died at various stag-
es from E10.5 to the neonatal stage (Table 1). Sos1EK/EK embryos 
showed subcutaneous edema and hemorrhage, suggesting severe 
impairment of cardiovascular function (Figure 2A). Histological 
analysis of E15.5 Sos1EK/EK embryos showed several cardiac defects, 
including secundum ASD (n = 5/5 embryos), ventricular septal 
defect (n = 4/5 embryos), aortic valvular (AV) stenosis (AS) due to 
thickened leaflets (n = 3/5 embryos), interventricular septal (IVS) 
and right ventricular hypertrophy (n = 3/5 embryos), and pericar-
dial effusions (n = 5/5 embryos) (Figure 2B). Secundum ASD, a 
typical type of ASD diagnosed in NS patients, was also observed 
in Sos1+/EK embryos, while only foramen ovale was observed in WT 
embryos (data not shown).

To assess what part of the developing heart might be involved 
in leading to these phenotypes, we examined the expression pat-
terns of Sos1 in this organ at E13.5. We observed that Sos1 protein 
was predominantly expressed in the aortic arch, pulmonary trunk, 
and the semilunar and the atrioventricular valves (Supplemental 
Figure 1; supplemental material available online with this article; 
doi:10.1172/JCI43910DS1). This expression pattern was similar in 
the WT and mutant embryos (Supplemental Figure 1).

Developmental remodeling of cardiac tissues involves substantial 
cell proliferation and apoptosis at specific times and regions, such 
as in the developing valves of aortic and pulmonary trunk and the 
upper part of the IVS (24). We investigated cell proliferation using 
BrdU staining and apoptosis using TUNEL assay in the upper IVS 
region (Figure 3A) and AV leaflets (Figure 3B) in E15.5 embryos. 
At both sites, we observed increased BrdU labeling and a decreased 
number of TUNEL-positive cells in Sos1EK/EK embryos compared 
with those of WT littermate controls, which could account for or 
contribute to the thickened AV and hypertrophic IVS (Figure 2B 
and Figure 3, A and B). These data suggest that aberrant patterns 
of cell proliferation and apoptosis are the cause of thickening of the 
semilunar valve and septal defects in the Sos1EK/EK mice.

The few Sos1EK/EK mice that were born had a significantly lower 
life expectancy (Figure 1G). Histological analysis of these mice 
at the age of 3 months showed severe AS due to thickened leaf-
lets (n = 3 mice; Figure 3C). Masson trichrome staining revealed 
epicardial and myocardial fibrosis (Figure 3D and Supplemental 

n

P	

	

χ2	

	

0.29 
0.23 
1.14 

Figure  2)  and  degenerated 
myocardium (Figure 3E) in 
Sos1EK/EK  hearts.  Interest-
ingly, we observed a signifi-
cant  amount  of  adipocyte 
infiltration in the ventricular 
myocardium and in the sur-
rounding blood vessels in the 
Sos1EK/EK hearts (Figure 3E). 
None  of  these  phenotypes 
were observed in WT litter-
mates, whereas a small num-
ber of adipocytes were seen 
in  the  Sos1+/EK  hearts  (data 
not shown). Taken together, 
these data suggest that Sos1EK 
homozygosity  caused  mul-
tiple cardiac defects, similar to those in humans with NS, as well 
as a significant degree of embryonic lethality.

0.59 
0.891 
0.566 
0.223 
< 0.0001 
< 0.0001 
0.263 

85
13
29
33
54
126
36

3 
19 

35.14 
2.67 

Sos1+/EK mice develop cardiac hypertrophy. Although subcutaneous 
edema, hemorrhage, and pericardial effusion were observed in 
some Sos1+/EK embryos (Figure 2, A and B), we obtained Sos1+/EK 
mice at the expected frequency (Table 1). Histological analysis of 
Sos1+/EK mice showed that some of them developed AS due to thick-
ened leaflets, starting at the age of 8.5 months (n = 4/10 mice; Fig-
ure 4A). Although NS patients with SOS1 mutation develop PS, we 
did not observe PS in the Sos1+/EK hearts (data not shown).

With or without valve dysfunction, about 20% of SOS1 mutant-
associated NS patients develop HCM (7, 8). We monitored male 
Sos1+/EK  mice  using  echocardiography  monthly,  beginning  at  
5 months. The echocardiograms of approximately 5- to 7-month-
old WT and Sos1+/EK mice were comparable (data not shown). At 
8 months, while Doppler examinations of aortic blood velocity 
suggested normal valve function (130 ± 34.6 cm/s; Figure 4B), 
maximal wall thickness in the IVS was significantly increased in 
Sos1+/EK mice (n = 7 mice) when compared with that of WT lit-
termate controls (n = 5 mice) (1.0 ± 0.11 mm vs. 0.7 ± 0.07 mm;  
P < 0.001; Figure 4C and Table 2). In humans, the left ventricular 
end-diastolic diameter (LVDd) is indexed for the body weight to 
enable comparison among individuals with significantly differ-
ent body size (25). Because of the significant differences in body 
weight between WT and Sos1+/EK mice (see below), we normalized 
the LVDd to the body surface area (BSA) of the mice. The indexed 
parameters showed a significantly increased LVDd in Sos1+/EK mice 
when compared with that of WT littermates. Taken together, 
these results indicated that Sos1+/EK mice developed left ventricular 
hypertrophy (LVH; Table 2). Importantly, Sos1+/EK mice had normal 
blood pressure, suggesting that hypertension was not the cause of 
their LVH (Supplemental Table 1).

Wheat germ agglutinin staining of the Sos1+/EK hearts at 8.5 
months of age showed increased size and irregular shape of car-
diomyocytes (Supplemental Figure 3). Masson trichrome stain-
ing of Sos1+/EK hearts showed severe fibrosis of the left ventricular 
walls (Figure 4D), with both focal (Figure 4E) and interstitial (Fig-
ure 4F) fibrosis. Collagen III staining further confirmed signifi-
cantly increased collagen deposits in Sos1+/EK hearts (Figure 4G). 
In addition, the cardiomyocytes around the fibrotic areas showed 
TUNEL-positive nuclei, indicating cardiomyocyte death in the 
Sos1+/EK mice (Figure 4H). Several hypertrophic markers, includ-
ing atrial natriuretic factor (Anf), B-type natriuretic peptide (Bnp), 

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 12      December 2010 

4355

Downloaded on December  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43910

research article

Figure 2
Cardiac defects in Sos1EK/EK embry-
os. (A) Gross appearance of E13.5 
embryos. (B) Representative H&E-
stained transverse sections of hearts 
from E15.5 embryos. Note edema 
(asterisks),  AS  (red  arrowhead), 
ASD (cyan arrows), ventricular sep-
tal defect (VSD, blue arrowhead), 
right ventricular hypertrophy (open 
circle), and IVS hypertrophy (open 
triangle)  in  Sos1EK/EK  hearts.  PV, 
pulmonary valve. PV and AV original 
magnification, ×10. Four-Chamber 
sections original magnification, ×4. 

and myosin heavy polypeptide 7, cardiac muscle, β (Myh7), were 
overexpressed in the Sos1+/EK hearts (Figure 4I). Taken together, 
our results show that Sos1+/EK mice develop pathological cardiac 
hypertrophy, which is also seen in NS patients.

Short stature and facial dysmorphia in Sos1+/EK mice. NS is character-
ized by short stature (7, 8). Similarly, Sos1+/EK and Sos1EK/EK mutant 
mice showed gene dosage-dependent reduced body size, weight, 
and length, with preservation of overall body proportions when 
compared with WT littermates (Figure 5, A and B). As with NS 
patients, Sos1+/EK and Sos1EK/EK faces tended to be more “triangular” 
(Figure 5C), and mutant mice also tended to have blunter snouts 
caused by depression of the anterior frontal bone (Figure 5C). We 
further characterized the bone structure and quantified the actual 
dimensions of the mouse skull using CT scans (Figure 5D). Sos1+/EK  
and Sos1EK/EK mice had significantly shorter skull lengths and 
increased inner canthal distances when compared with those of 
WT littermates at the age of 3 months (Figure 5E).

Hematological disorders in Sos1+/EK mice. Individuals with NS often 
have unexplained hepatosplenomegaly and some develop MPD 
(3). By the age of 5 months, Sos1+/EK mice developed splenomegaly  
(n  =  8/8  mice;  Figure  6A)  resulting  from  extramedullary 
hematopoiesis, with increased erythropoiesis and increased num-
bers of megakaryocytes (Figure 6B). Blood smears from the Sos1+/EK 
mice showed an increased number of neutrophils (n = 3/8 mice; 

Figure 6C). Sos1+/EK mice showed a subtle but significant increase 
of leukocytes in peripheral blood counts when compared with WT 
littermates (4.74 ± 3.37 × 103/μl vs. 2.06 ± 1.08 × 103/μl; P < 0.05; 
Supplemental Table 2) at the age of 5 months. Flow cytometric 
analysis confirmed the myeloid expansion in the bone marrow and 
spleen of Sos1+/EK mice (Figure 6D and Supplemental Figure 4).  
Bone marrow progenitors from Sos1+/EK mice showed increased 
sensitivity to IL-3 or GM-CSF and also gave rise to factor-inde-
pendent colonies (Figure 6E). These results indicate that Sos1EK is 
associated with the development of hematological disorders.

Signaling abnormalities in Sos1EK hearts. Human cells that overex-
press SOS1E846K show increased RasGEF activity, as manifest-
ed by sustained RAS activation and increased levels of p-ERK in 
response to EGF stimulation (8). Consistent with these findings, 
we observed increased Ras-GTP (Figure 7A) and p-Erk1/2 (Figure 
7B) levels in Sos1+/EK and Sos1EK/EK hearts.

Several studies have shown that Sos1 also can function as a 
RacGEF in transfected cell systems (14). We also observed a gene 
dosage-dependent increase in the level of endogenous Rac1-GTP 
in Sos1+/EK and Sos1EK/EK hearts (Figure 7C), providing the first evi-
dence to our knowledge that Sos1EK also functions as a RacGEF 
under physiologically relevant conditions.

We also asked whether Sos1EK leads to increased activation of 
other MAPK pathway components or alterations in other sig-

4356	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 12      December 2010

Downloaded on December  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43910

research article

Figure 3
Cardiac defects in Sos1EK/EK mice. 
(A  and  B)  Immunofluorescence 
staining  for  BrdU  (top  rows)  and 
TUNEL  (bottom  rows)  in  the  (A) 
interventricular septum and (B) aor-
tic valve leaflets of E15.5 embryos. 
Graphs  show  quantification  with 
error bars indicating SD. *P < 0.05, 
**P < 0.01, ***P < 0.001 when com-
pared with WT littermates. (C) H&E-
stained  sections  showing  AS  in 
3-month-old Sos1EK/EK mice. (A–C) 
Original magnification, ×4. (D) Mas-
son trichrome staining of heart tis-
sue, showing fibrosis in 3-month-old 
Sos1EK/EK mice. Note blue collagen 
staining in the left atrial (LA) epicar-
dium (blue arrow) (left panel original 
magnification, ×4), with a magnified 
view in the middle panel (original 
magnification, ×20), as well as in 
right ventricular epicardium (right 
panel, original magnification, ×10). 
(E)  Masson  trichrome  staining  of 
Sos1EK/EK hearts. Black arrows indi-
cate degenerating cardiomyocytes. 
Blue arrows indicate adipocytes in 
the area surrounding (or around) the 
blood vessels (left panel, original 
magnification, ×10) and within the 
interventricular septum (right panel, 
original magnification, ×20).

naling pathways that are associated with cardiac hypertrophy. 
We  profiled  kinase  phosphorylation  using  phospho-kinase 
array (Figure 7D) and validated the results using immunoblot-
ting. Interestingly, we found that the level of phosphorylated-
Stat3 at Tyr705 (p-Stat3) was significantly increased in Sos1+/EK  
and Sos1EK/EK hearts (Figure 7, D and E). In contrast, we did 
not detect consistent activation of phosphorylation of Stat3 at 
Ser727, Stat5, p38, JNK, or Akt in all of the Sos1EK hearts (Sup-
plemental Figure 5). Both p-Erk1/2 and p-Stat3 can translocate 
to the nucleus and increase transcriptional initiation (26, 27). 

We observed increased nuclear staining of both p-Erk1/2 and 
p-Stat3 in Sos1+/EK and Sos1EK/EK hearts (Figure 7F). In addition, 
overexpression of SOS1E846K increased the transcriptional 
activities of STAT3 when compared with WT SOS1 in human 
cells (Figure 7G), which further confirmed the activation of 
STAT3 by SOS1E846K mutation.

Previous studies suggest that Rac1 can induce STAT3 phos-
phorylation at Tyr705, but not at Ser727, by promoting autocrine 
production of IL-6 (28, 29). Interestingly, we detected increased 
expression of IL-6 in Sos1+/EK and Sos1EK/EK hearts (Figure 7H). 

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 12      December 2010 

4357

Downloaded on December  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43910

research article

Figure 4
Cardiac defects in Sos1+/EK mice. (A) Representative H&E-stained transverse sections, showing AS (arrow) in Sos1+/EK hearts. Ao, aorta. 
Original magnification, ×10. (B) Representative Doppler image, with measurement of ascending aortic peak velocity of an 8-month-old Sos1+/EK 
mouse. (C) Representative M-mode (left parasternal short axis view; top) and 2D (left parasternal long and short axes; bottom) echocardio-
graphic images obtained from 8-month-old mice. Green bars (bottom) indicate the thickness of interventricular septum. IVS, IVS thickness; 
LVId, left ventricular dimension at diastole; LVIs, left ventricular dimension at systole; LVPW, left ventricular posterior wall thickness. (D–F) 
Representative Masson trichrome staining showing fibrosis in the hearts of a 9-month-old Sos1+/EK mouse (right) but not in a WT littermate (left).  
(D) Original magnification, ×4. (E and F) Original magnification, ×10. (G) Immunofluorescence staining of collagen III (Col III) in the left ventricular 
wall. Original magnification, ×40. (H) TUNEL assay costained with the cardiomyocyte marker Troponin T, showing cardiomyocyte death in a 
Sos1+/EK heart; the right panel shows a higher magnification view. Arrows indicate TUNEL positive cells. Original magnification, ×40 and ×64.  
(I) Representative quantitative real-time PCR results, showing increased expression of cardiac hypertrophic markers in the Sos1+/EK hearts. Error 
bars indicate SD. **P < 0.01; ***P < 0.001.

These results suggest that Sos1EK increased Rac activity that might 
induce Stat3 activation through autocrine IL-6. Erk1/2 and Stat3 
are known to be involved in cardiac hypertrophy (30–33), and it 
is likely that both signaling molecules contribute to the cardiac 
phenotypes observed in the Sos1EK mice.

Prenatal treatment with MEK inhibitor improves the embryonic lethal-
ity and NS features in Sos1EK/EK mice. We asked whether treating 
pregnant mothers with a small-molecule RAS/MAPK pathway 
inhibitor could diminish the embryonic lethality or phenotypic 
features of Sos1 mutant offspring. PD0325901 selectively binds 
to and inhibits MEK, resulting in reduction of the phosphoryla-
tion and activation of Erk1/2 (19, 34–36). PD0325901 was shown 
to be efficient in preventing tumor incidence and growth in 
mice at a dosage of 1 mg/kg of body weight (mg/kg) (37). There-
fore, we administered PD0325901 (1 mg/kg) daily i.p. to preg-
nant mice from Sos1+/EK intercrosses (n = 6 mice), beginning at  
7 days post coitum and continuing (in nursing females) until P9. 
Beginning at P10, the drug was injected individually into pups 
(i.p.) until P28. Prenatal administration of the drug completely 
rescued the prenatal lethality of homozygous mice, such that 
they were born at the expected Mendelian ratio (n = 9 out of 36 
mice, 25%; χ2 = 2.67, P = 0.263; Table 1). We examined 3 Sos1EK/EK  
mice at P2 and found a normal heart structure in 2 of the mice, 

while the third had died and had a secundum ASD (Figure 8A). 
Immunoblotting indicated that the phosphorylation of Erk1/2 
had been normalized, whereas p-Stat3 levels remained high in 
Sos1EK/EK hearts (Figure 8B). One Sos1EK/EK mouse died at P14 
with a secundum ASD and hypertrophic right ventricles with 
dilated epicardial vessels (Figure 8C). The rest of the Sos1EK/EK 

Table 2
Echocardiographic parameters of 8-month-old mice

 
BW (g) 
BSA (cm2) 
IVS (mm) 
LVDd (mm) 
LVDd index (mm/mm2) 
LVPW (mm) 
%FS 

Sos1+/+ 

44.80 ± 6.41 
56.47 ± 5.45 
0.70 ± 0.07 
4.05 ± 0.40 
0.072 ± 0.007 
0.83 ± 0.09 
42.19 ± 6.01 

Sos1+/EK 

30.38 ± 1.05 
43.67 ± 1.00 
1.00 ± 0.11 
3.64 ± 0.35 
0.083 ± 0.006 
0.88 ± 0.09 
44.69 ± 5.43 

P

0.0006
0.0005
0.0002
0.0962
0.0138
0.3711
0.4767

IVS, IVS thickness; LVPW, left ventricular posterior wall thickness; 
%FS, percentage fractional shortening. Numbers are shown with ± SD. 
n = 5 for Sos1+/+; n = 7 for Sos1+/EK. BW, body weight; BSA, body sur-
face area; LVDd left ventricular end-diastolic diameter.

4358	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 12      December 2010

Downloaded on December  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43910

research article

Figure 5
Short stature and facial dysmorphia in Sos1EK mice. (A) Representative appearance of 3-month-old littermates, showing reduced body length 
and size in Sos1 mutant mice. (B) Body weights of WT and mutant male mice with lines fit by linear regression. (P < 0.001 for Sos1+/EK versus 
WT and P < 0.05 for Sos1EK/EK versus WT.) (C) Facial defects in 3-month-old Sos1 mice. Arrowheads indicate blunt noses of mutant mice.  
(D) CT scans of 3-month-old mice. A sagittal projection (top row) and a coronal projection (bottom row) are shown. Numbers refer to the mea-
surements shown in E. (E) Morphometric characteristics of the mice. Measurements were obtained on the CT sections at the same axial, coronal, 
and sagittal reference position in all mice (n = 3 for each genotype). Numbers are shown with SD. *P < 0.05, **P < 0.01, ***P < 0.001.

mice survived (n = 5 mice) and, unlike untreated Sos1EK/EK mice, 
had no anatomical abnormalities in their hearts at the age of  
3 months (n = 3 mice; Figure 8D).

The body weight of PD0325901-treated Sos1EK/EK mice increased 
and was comparable to either treated or untreated Sos1+/EK mice 
but was still lower when compared with either treated or untreated 
WT mice (Figure 8E). Furthermore, CT scans of the skull of the 
treated Sos1+/EK and Sos1EK/EK mice showed improvement of their 
facial dysmorphia at the age of 3 months (Figure 8F).

These data suggest that prenatal inhibition of Erk1/2 acti-
vation by the MEK inhibitor PD0325901 successfully rescued 
the embryonic lethality and reduced the penetrance of cardiac 
defects of Sos1EK/EK mice.

Discussion
We describe here what we believe to be the first mouse model for 
NS caused by Sos1 mutation. Analogous to that in humans, het-
erozygosity of this mutation leads to a number of phenotypes, 
such as reduced growth, facial dysmorphia, hematological defects, 
and cardiac hypertrophy. We observed that in the heart, Sos1EK 
leads to Ras activation and, importantly, Rac activation as well. 
In addition to increased activation of the Ras/MAPK pathway, 
we unexpectedly observed increased activation of Stat3. Homo-
zygous Sos1EK mutation resulted in a severe NS phenotype, with 
some embryos dying as early as E10.5, whereas others were born 

and lived for at least 3 months. Examination of late-stage Sos1EK/EK 
embryos revealed a spectrum of severe cardiac abnormalities.

Distinct phenotypes of Sos1EK mice. Our studies indicate that the 
phenotypes in Sos1EK mice and previous NS-associated Ptpn11D61G 
or other Ptpn11 mouse models were overlapping to some degree 
but distinguishable (38–43). First, Ptpn11D61G/D61G were completely 
embryonic lethal, whereas we obtained a small number of Sos1EK/EK 
mice (41). Second, we observed several distinct cardiac phenotypes 
in Sos1EK/EK mice, such as epicardial fibrosis and adipocyte infiltra-
tion, which were not detected in any of the Ptpn11 models (38–43). 
Third, LVH was not documented in Ptpn11 models; indeed, mice 
with homozygous Ptpn11D61G or heterozygous Ptpn11D61Y mutations 
have dilated cardiomyopathy (41, 42). By contrast, Sos1+/EK mice 
developed LVH and ventricular fibrosis. Although the majority of 
the Sos1+/EK mice with AS showed LVH, we also observed LVH in 
several Sos1+/EK mice without AS and with normal blood pressure.
SOS1EK mutations appeared to have selective effect on semilu-
nar valves, whereas Ptpn11DG mice had more of an effect on atrio-
ventricular valves. In addition, although PS is the major clinical 
cardiac feature of NS patients carrying SOS1 mutation, neither 
histological analysis nor Doppler echocardiography detected PS 
in our mouse model (data not shown). On the other hand, AS was 
observed frequently in Sos1EK/EK mice and in older Sos1+/EK mice. 
Finally, in addition to activation of Ras and Erk, we found that 
Rac and Stat3 were also activated in Sos1EK mice, which was not 

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 12      December 2010 

4359

Downloaded on December  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43910

research article

Figure 6
Sos1+/EK mice develop hematological disorder. (A) Representative view showing splenomegaly in Sos1+/EK mice, with quantification graphed  
(n = 8). Error bars indicates SD. **P < 0.01. (B) Representative H&E-stained sections of spleens, showing increased numbers of megakaryocytes 
(white arrowheads) and massive increase of red pulp (bottom panel) in the Sos1+/EK mice. Immunohistochemistry staining showing CD41-posi-
tive megakaryocytes (brown cells; right panels). Original magnification, ×75. (C) Blood smears showing an increased number of neutrophils in 
Sos1+/EK mice. Original magnification, ×100. (D) Flow cytometric analysis of bone marrow and spleen, showing increased percentages of myeloid 
lineage (Mac1+ and Mac1+Gr1+) cells in Sos1+/EK mice (P < 0.05 for bone marrow; P < 0.01 for spleen). Numbers indicate the percentage of posi-
tively-stained cells. (E) Increased myeloid colony formation of Sos1+/EK bone marrow in the absence or presence of the indicated concentrations 
of GM-CSF or IL-3 (P < 0.05 and P < 0.01, respectively).

found in the Ptpn11 models (38–40, 44). It is possible, if not likely, 
that the common phenotypes observed in Sos1 and Ptpn11 mod-
els, such as growth delay, craniofacial features, hematological dis-
orders, and some cardiac defects, were due to the enhanced Erk 
activation seen in both models, whereas the distinct features in 
the Sos1 model described above were due to the selective activation  
of Rac and/or Stat3.

Distinct molecular signaling in Sos1EK mice. SOS1 not only has a 
RasGEF activity but can act as a RacGEF in cultured cells. These 
GEF activities are mediated by distinct Cdc25 homology and Dbl 
homology (DH) domains, respectively (45, 46), in SOS1. Rac is 
a key molecule in integrating diverse stimuli and transducing 
signals in the cardiovascular system (47). Several studies indicate 
that Rac activation can contribute to cardiac hypertrophy in vitro 
and in vivo (48–52). Our study provides the first in vivo evidence 
to our knowledge for Rac activation by gain-of-function Sos1 
proteins under endogenous levels of expression and suggests a 
role for Rac activation in the pathogenesis of Sos1-associated NS. 
Since the E846 residue is not in the Rac-binding DH domain of 
the Sos1 protein, the precise mechanism of the activation of Rac 
needs further investigation.

Our study also suggests that Stat3 activation contributes to the 
cardiac defects in our mouse model. The transcription factor Stat3 

participates in a wide range of physiological processes, including 
proliferation, apoptosis, tumor growth, and angiogenesis (26). 
Stat3 activation also promotes cardiomyocyte survival and hyper-
trophy (31). Stat3 can be activated by the G protein–coupled recep-
tor via Rac1 (53–60). Some studies suggested that Rac1 directly 
binds to and regulates STAT3 (61, 62), while other studies sug-
gested that Rac1 induces cytokine secretion that activates STAT3 
(28, 29, 63). Our data suggest that Sos1EK mutation causes Rac acti-
vation and increased production of IL-6, leading to Stat3 activa-
tion in the heart.

Small-molecule treatments for Sos1EK mice. Several studies suggest 
that targeting RAS/MAPK signaling might be a powerful thera-
peutic strategy against cardiac hypertrophy (64). Our data pro-
vide what we believe to be the first example of successful rescue 
of embryonic lethality and reduced penetrance of cardiac defects 
by prenatal treatment with a small-molecule MEK inhibitor in a 
NS mouse model. However, some cardiac defects still exist in the 
Sos1EK/EK mice, possibly because of the persistently activated Stat3. 
Inhibitors for Rac and/or Stat3 may be necessary to further relieve 
the cardiac defects in Sos1EK/EK mice. Previously, the use of the MEK 
inhibitor U0126 in a transgenic Ptpn11 NS mouse model during 
pregnancy reduced the craniofacial defects (40). Our PD0325901-
treated Sos1EK mice also showed improved skull shape. The growth 

4360	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 12      December 2010

Downloaded on December  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43910

research article

Figure 7
Altered signaling in Sos1EK hearts. (A) Ras-GTP levels are increased 
in mutant hearts. (B) p-Erk1/2 levels are increased in mutant hearts. 
(C) Rac-GTP levels are increased in mutant hearts. (D) The phos-
pho-kinase array detects phosphorylated proteins in WT and Sos1+/EK 
heart lysates (left panel). The right panel shows higher magnification 
of numbered spots on the left panel. Note increased levels of p-Erk1/2, 
p-Mek, and p-Stat3 in Sos1+/EK hearts. (E) Increased levels of p-Stat3 
in the mutant hearts. (F) Immunofluorescence staining of p-Erk1/2 and 
p-Stat3 in heart sections from 3-month-old mice. Note colocalization of 
p-Erk1/2 and p-Stat3 with the DAPI stain. Original magnification, ×40. 
(G) STAT3 reporter assay showing increased STAT3 transcriptional 
activities in cells cotransfected with SOS1 or SOS1E846K. **P < 0.01, 
***P < 0.01. neg, cotransfected with negative control vector. (H) Quan-
titative real-time PCR results showing increased expression of IL-6 in 
the Sos1EK hearts. Error bars indicate SD. n = 3 for each genotype.  
**P < 0.01, ***P < 0.001 when compared with WT littermates.

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 12      December 2010 

4361

Downloaded on December  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43910

research article

4362	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 12      December 2010

Downloaded on December  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43910

Figure 8
Prenatal treatment with the MEK inhibitor blocks development of NS 
features. (A) H&E-stained sections of hearts from PD0325901-treated 
mice at P2. The asterisk indicates ASD. Top panel, original magnifica-
tion, ×20. Bottom panel, original magnification, ×4. (B) Immunoblot 
showing effects of PD0325901 treatment on Erk1/2 and Stat3 acti-
vation. (C) H&E-stained section of a PD0325901-treated Sos1EK/EK 
mouse that died at P14. Note ASD (arrow), hypertrophic right ven-
tricle wall (asterisk), and dilated epicardial vessels (arrowhead). (D) 
Representative sections of heart tissue of 3-month-old Sos1EK/EK mice 
with or without PD0325901 treatment. H&E-stained sections showing 
AS in the untreated mice (black arrowhead; row 1, original magnifi-
cation, ×10). Masson Trichrome–stained sections showing fibrosis in 
untreated mice (rows 2–4). Note blue collagen staining (blue arrow) in 
left ventricular epicardium (row 2, original magnification, ×4), right atrial 
(RA) epicardium (row 3, original magnification, ×10), and right ventricu-
lar epicardium and myocardium (row 4, original magnification, ×10). 
Scale bar: 500 μm. (E) Body weight of treated and untreated male 
mice fit by linear regression. P < 0.01 for both PD0325901-treated 
Sos1+/EK mice versus PD0325901-treated WT mice and PD0325901-
treated Sos1EK/EK mice versus PD0325901-treated WT mice. PD, 
PD0325901. (F) CT scans of treated and control mice (top row). A 
sagittal projection (top row) and a coronal projection (bottom row) are 
shown. Skull measurements are shown as in Figure 5E. *P < 0.05 
when compared with WT.

of the PD0325901-treated Sos1EK/EK mice was improved but not 
normalized. In fact, the growth of the PD0325901-treated Sos1+/EK 
mice remained the same as that of the untreated ones, suggesting 
that inhibiting Erk1/2 during pregnancy and early age might not 
be sufficient for normalizing the short statue in NS. Our previous 
studies showed that strong mutant alleles of PTPN11 cause both 
perinatal and postnatal growth defects, whereas others caused 
only postnatal defects (41, 42). Together with the present Sos1 
model, our studies suggest that there is a distinct pathogenesis 
of these growth defects.

In summary, our data suggested that Ras and Erk1/2, as well as 
Rac and Stat3, are activated and may all contribute to the cardiac 
defects of the Sos1EK mouse models. Normalizing all of these path-
ways might be required for successful amelioration of the entire 
spectrum of observed phenotypes. Given the gene-specific dif-
ferences in NS phenotypes that our mouse models have revealed 
(41, 42), it also is possible that distinct treatment regimes will be 
warranted for different NS patients based on the specific genetic 
mutation they carry.

Methods
Generation of Sos1 mutant mice. All animal experiments were performed 
according to protocols approved by the Institutional Animal Care and Use 
Committee of Harvard Medical School. Briefly, the Sos1 E846K mutation 
was introduced by site-directed mutagenesis and subsequently incorporat-
ed into a targeting vector, with a unidirectional Cre-mediated recombina-
tion system. The targeting construct contains an inverted exon 16, with the 
mutation E846K flanked by 2 wloxP and 2 mloxP sites in opposite orienta-
tions in intron 17 (Figure 1A). The targeting vector was linearized and used 
to electroporate J1 ES cells (129Sv background). Long-range PCR was used 
to screen the G418-resistant clones (Figure 1A and Supplemental Figure 6). 
Correctly targeted ES clones were microinjected into C57BL/6 blastocysts, 
and the resulting chimeras were mated with ACT-FLPe transgenic mice 
(C57BL/6J background; The Jackson Laboratory) to delete the Neo cassette 
by Flp-mediated recombination. Offspring bearing the targeted locus were 

research article

crossed with EIIA-Cre transgenic mice (C57BL/6J background) to obtain 
heterozygous mutant mice (Sos1+/EK mice), which were then backcrossed to 
C57BL/6J mice for an additional 4 generations and then crossed once with 
129S1/SvImJ to obtain offspring that were approximately 50% C57BL/6J 
and 50% 129S1/SvImJ background. These offspring were then intercrossed 
(Sos1+/EK × Sos1+/EK) to obtain homozygous mice (Sos1EK/EK mice).

Histology.  Hearts  were  excised  from  WT  and  mutant  mice,  washed 
in Dulbecco’s PBS (DPBS), arrested in 1 M KCl solution, fixed in 4% 
paraformaldehyde in DPBS at 4°C for fewer than 16 hours, and processed 
for paraffin embedding. Tissues were serially sectioned (5-μM sections) in 
the transverse or sagittal plane. H&E staining and Masson trichrome stain-
ing were used to define cellular architecture, and sections were analyzed 
by an experienced cardiac pathologist who was blinded to the genotypes. 
Peripheral blood smears were prepared from tail blood and stained with 
Wright-Giemsa solution.

RT-PCR  and  real-time  PCR.  Tissues  were  pretreated  with  RNAlater 
(Ambion) solution overnight at 4°C. RNA was extracted using TRIzol 
(Invitrogen), treated with DNase (Invitrogen), and purified by using the 
PureLink RNA Mini Kit (Invitrogen). RNA was subjected to SuperScript 
One-Step RT-PCR (Invitrogen) for specific gene amplifications or to the 
High-Capacity cDNA Archive Kit (ABI) to generate cDNA for real-time 
PCR. Messenger RNA-specific primers (Supplemental Table 3) and Power 
SYBR Green PCR Master Mix (ABI) were used for real-time PCR. TaqMan 
Gene Expression Assays for GAPDH (ABI) and TaqMan Universal PCR 
Master Mix (ABI) were used as controls.

Immunoblotting, GTPase activity assay, and phospho-kinase array. Left and 
right ventricles or other tissues were lysed in RIPA buffer (50 mM Tris-HCl, 
pH 7.4; 1% NP-40; 150 mM NaCl; 0.5% sodium deoxycholate; 0.1% SDS) 
containing a Mini Tablet Protease Inhibitor (Roche) and phosphatase 
inhibitors (25 μM sodium fluoride and 50 μM sodium orthovanadate). 
For each sample, 80 μg protein was subjected to SDS-PAGE, followed by 
transfer to nitrocellulose membranes. Blots were incubated with primary 
antibodies at 4°C overnight and secondary antibodies for 1 hour at room 
temperature and then developed with Amersham ECL Plus Western Blot-
ting Detection Reagents (GE Healthcare). To quantify Ras-GTP and Rac-
GTP in cardiac lysates, Ras and Rac Activation Assay Kits (Millipore) were 
used according to the manufacturer’s instructions. The Phospho-Kinase 
Array Kit (Proteome Profiler Antibody Array, R&D Systems) was used 
according to the manufacturer’s instructions.

Echocardiographic studies. Mice were anesthetized using an isoflurane 
vaporizer (VetEquip), and each limb was placed on the ECG leads on a Vevo 
Mouse Handling Table (VisualSonics Inc.) to maintain body temperature 
at 37°C. Chest hair was removed with depilatory cream, and transthoracic 
echocardiography was performed using a Vevo 770 High-Resolution In Vivo 
Micro-Imaging System and an RMV 707B Scanhead (VisualSonics Inc.). 
Heart rates were 500–550 beats per minute. Images were acquired in 2D (left 
parasternal long and short axes) and M-mode (left parasternal short axis). 
Measurements of 3 consecutive beats of M-mode tracings were averaged 
and used for calculating left ventricular end-diastolic diameter (LVDd), left 
ventricular end-systolic diameter (LVSd), and wall thickness (IVS and left 
ventricular posterior wall). Left ventricular fractional shortening (%) was 
calculated as follows: (LVDd – LVSd)/LVDd × 100. Wall thickness and LVDd 
were indexed for BSA to enable comparison among mice of significantly dif-
ferent size (25). BSA was calculated as follows (25): BSA = (BW × 9.5)2/3. For 
Doppler studies, to measure the aortic and pulmonary blood flow velocity, 
the probe was moved to a slightly higher position from the regular long and 
short axis positions, respectively, and the angle of the probe was adjusted 
until a good waveform was observed. The peak velocity was averaged from  
3 consecutive waveforms. All echocardiographic measurements were done 
by a single experienced observer blinded to mouse genotype.

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 12      December 2010 

4363

Downloaded on December  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43910

research article

Blood pressure. Blood pressure was measured in trained conscious mice 
using a Visitech BP-2000 Analysis System. Mice were kept in the restrainer 
on a heated device to maintain body temperature at 37°C during the mea-
surements. The mice were “trained” to the procedure twice every day for 3 
consecutive days, and data were recorded over the following 2 days. For each 
mouse, at least 30 readings were collected and used for statistical analysis.

CT. CT scans were performed with the preclinical imaging eXplore Vista 
PET/CT machine, using 40 kVolt, 140 μAmp, and 1-shot and standard res-
olution (GE Healthcare). Morphometric parameters were measured using 
eXplore Vista CT software.

Immunohistochemistry, immunofluorescence staining, and TUNEL assay. Tis-
sue sections were deparaffinized, rehydrated, treated with 0.1 M citric acid 
(pH 6.0), and blocked with 5% normal donkey serum in PBS. Phospho-spe-
cific antibodies against ERK1/2 (Thr202/Tyr204), STAT3 (Tyr705), STAT3 
(Ser727), STAT5 (Tyr694), JNK1/2 (Thr183/Tyr185), p38 (Thr180/Tyr182), 
and Akt (Ser473) were obtained from Cell Signaling Technology. Anti-
BrdU antibody was obtained from Sigma-Aldrich. Anti-Sos1 antibody was 
obtained from Santa Cruz Biotechnology Inc. For immunohistochemistry, 
Biotin-SP–conjugated secondary antibodies (Jackson ImmunoResearch Inc.) 
and the VECTASTAIN Elite ABC System (Vector Laboratories) were used 
for detection. For immunofluorescence, Dy-Light–conjugated secondary 
antibodies (Jackson ImmunoResearch Inc.) were used for detection. TUNEL 
assays to detect apoptotic cells were performed using the In Situ Cell Death 
Detection Kit (Roche), according to the manufacturer’s instructions.

Flow cytometry. Single cell suspensions from bone marrow and spleen 
were prepared as described previously (41) and washed in PBS containing 
2% fetal bovine serum. Fc receptor-mediated binding was blocked by pre-
incubation with anti-CD16/CD32. Aliquots of 0.5 × 106 cells were stained 
with monoclonal antibodies specific for Mac-1 (CD11b), Gr-1, B220, CD4, 
and CD8 conjugated to PE, allophycocyanin (APC), or FITC. All antibodies 
were obtained from BD Pharmingen. Flow cytometry was performed with 
FACSCalibur (BD) and analyzed with FlowJo software.

Bone marrow colony-formation assays. Myeloid colony formation by WT and 
mutant bone marrow cells was examined in the presence or absence of IL-3 
or GM-CSF stimulation. Bone marrow cells were collected from the femurs 
by flushing cold PBS into the bone with a 23-gauge needle. The cell suspen-

sion was filtered though a 40-μm cell strainer. Cells were collected by cen-
trifugation, resuspended in IMDM, seeded (105 cells/plate) in MethoCult 
M3234 medium (Stemcell Technologies) with IL-3 or GM-CSF at various 
concentrations, and colonies were enumerated after 12 days of incubation.

STAT3 reporter assay. 293T cells were transfected with pcDNA3 vector, 
pcDNA3-SOS1, or pcDNA3-SOS1E846K with luciferase reporters, accord-
ingly. The Cignal STAT3 Reporter (luc) Kit (SA Biosciences) was used 
according to the manufacturer’s instructions. The Dual-Luciferase Reporter 
Assay System (Promega) was used for detecting luciferase luminescence.

Small-molecule treatment. PD0325901 was resuspended in vehicle (0.5% 
hydroxypropylmethylcellulose with 0.2% Tween80) and injected i.p. (1.0 
mg/kg body weight) into pregnant mice daily, beginning on gestational 
day 7.5 (E7.5) and continuing until P9. Vehicle-injected mice served at 
controls. Beginning at P10, PD0325901 or vehicle alone was injected (i.p.) 
directly into pups every other day, until 4 weeks after birth.

Statistics. Continuous variables, such as ECG intervals and conduction 
parameters, were measured by 2 observers and summarized as the mean ± SD. 
Two-way ANOVA was used for comparisons among genotypes. The Fisher 
exact t test and 2-tailed t test with Welch’s correction were used for categorical 
variables. A P value of less than 0.05 was considered significant.

Acknowledgments
We thank Libin Wang, Elizabeth Sparks, Katarina Riesner, Shuy-
an Wang, and Erica Tworog-Dube for technical assistance. This 
work is supported by NIH grant CA 84301 (to R. Kucherlapati), 
NHLBI NIH Syscode and LeDucq Foundation (to J.G. Seidman), 
NIH grants CA49132 and HL083273 (to B.G. Neel), and HHMI 
and LeDucq Foundation (to C.E. Seidman).

Received for publication June 2, 2010, and accepted in revised form 
September 15, 2010.

Address correspondence to: Raju Kucherlapati, Department of 
Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, Suite 
160, Boston, Massachusetts 02115, USA. Phone: 617.525.4445; 
Fax: 617.525.4440; E-mail: rkucherlapati@partners.org.

  1. Tidyman WE, Rauen KA. The RASopathies: develop-
mental syndromes of Ras/MAPK pathway dysregu-
lation. Curr Opin Genet Dev. 2009;19(3):230–236.

  2. Allanson JE. Noonan syndrome. Am J Med Genet C 

Semin Med Genet. 2007;145C(3):274–279.

  3. Hasle H. Malignant diseases in Noonan syndrome and 

related disorders. Horm Res. 2009;72(suppl 2):8–14.

  4. Choong K, Freedman MH, Chitayat D, Kelly EN, 
Taylor G, Zipursky A. Juvenile myelomonocytic 
leukemia and Noonan syndrome. J Pediatr Hematol 
Oncol. 1999;21(6):523–527.

  5. Tartaglia M, et al. Mutations in PTPN11, encod-
ing the protein tyrosine phosphatase SHP-2, cause 
Noonan syndrome. Nat Genet. 2001;29(4):465–468.
  6. Schubbert S, et al. Germline KRAS mutations cause 

Noonan syndrome. Nat Genet. 2006;38(3):331–336.
  7. Tartaglia M, et al. Gain-of-function SOS1 muta-
tions cause a distinctive form of Noonan syndrome. 
Nat Genet. 2007;39(1):75–79.

  8. Roberts AE, et al. Germline gain-of-function muta-
tions in SOS1 cause Noonan syndrome. Nat Genet. 
2007;39(1):70–74.

  9. Razzaque MA, et al. Germline gain-of-function 
mutations in RAF1 cause Noonan syndrome. Nat 
Genet. 2007;39(8):1013–1017.

  10. Pandit  B,  et  al.  Gain-of-function  RAF1  muta-
tions cause Noonan and LEOPARD syndromes 
with  hypertrophic  cardiomyopathy.  Nat  Genet. 
2007;39(8):1007–1012.

  11. Cirstea IC, et al. A restricted spectrum of NRAS 

mutations causes Noonan syndrome. Nat Genet. 
2010;42(1):27–29.

  12. Cordeddu V, et al. Mutation of SHOC2 promotes 
aberrant  protein  N-myristoylation  and  causes 
Noonan-like syndrome with loose anagen hair. Nat 
Genet. 2009;41(9):1022–1026.

  13. Schubbert S, Shannon K, Bollag G. Hyperactive 
Ras in developmental disorders and cancer. Nat Rev 
Cancer. 2007;7(4):295–308.

  14. Nimnual A, Bar-Sagi D. The two hats of SOS. Sci 

STKE. 2002;2002(145):pe36.

  15. Rossman KL, Der CJ, Sondek J. GEF means go: 
turning on RHO GTPases with guanine nucleo-
tide-exchange factors. Nat Rev Mol Cell Biol. 2005; 
6(2):167–180.

  16. Bar-Sagi D, Hall A. Ras and Rho GTPases: a family 

reunion. Cell. 2000;103(2):227–238.

  17. Bernards A, Settleman J. GEFs in growth factor sig-

naling. Growth Factors. 2007;25(5):355–361.

  18. Scita  G,  et  al.  Signaling  from  Ras  to  Rac  and 
beyond: not just a matter of GEFs. EMBO J. 2000; 
19(11):2393–2398.

  19. Sebolt-Leopold JS, Herrera R. Targeting the mito-
gen-activated protein kinase cascade to treat can-
cer. Nat Rev Cancer. 2004;4(12):937–947.

  20. Klein S, McCormick F, Levitzki A. Killing time for 

cancer cells. Nat Rev Cancer. 2005;5(7):573–580.

  21. Gibbs JB. Anticancer drug targets: growth factors 
and growth factor signaling. J Clin Invest. 2000; 
105(1):9–13.

  22. Xin HB, et al. Gene trap and gene inversion meth-
ods for conditional gene inactivation in the mouse. 
Nucleic Acids Res. 2005;33(2):e14.

  23. Lakso M, et al. Efficient in vivo manipulation of 
mouse genomic sequences at the zygote stage. Proc 
Natl Acad Sci U S A. 1996;93(12):5860–5865.

  24. Savolainen SM, Foley JF, Elmore SA. Histology atlas 
of the developing mouse heart with emphasis on 
E11.5 to E18.5. Toxicol Pathol. 2009;37(4):395–414.

  25. Cheung MC, et al. Body surface area prediction in 
normal, hypermuscular, and obese mice. J Surg Res. 
2009;153(2):326–331.

  26. Yu H, Jove R. The STATs of cancer--new molecular tar-

gets come of age. Nat Rev Cancer. 2004;4(2):97–105.

  27. Zehorai E, Yao Z, Plotnikov A, Seger R. The subcel-
lular localization of MEK and ERK--a novel nucle-
ar translocation signal (NTS) paves a way to the 
nucleus. Mol Cell Endocrinol. 2010;314(2):213–220.
  28. Faruqi TR, Gomez D, Bustelo XR, Bar-Sagi D, Reich 
NC. Rac1 mediates STAT3 activation by autocrine IL-6.  
Proc Natl Acad Sci U S A. 2001;98(16):9014–9019.

  29. Arulanandam R, Geletu M, Feracci H, Raptis L. 
Activated Rac1 requires gp130 for Stat3 activa-
tion, cell proliferation and migration. Exp Cell Res. 
2010;316(5):875–886.

  30. Kehat I, Molkentin JD. Extracellular signal-regu-
lated  kinase  1/2  (ERK1/2)  signaling  in  cardiac 
hypertrophy. Ann N Y Acad Sci. 2010;1188:96–102.
  31. Fischer P, Hilfiker-Kleiner D. Survival pathways in 
hypertrophy and heart failure: the gp130-STAT3 

4364	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 12      December 2010

Downloaded on December  2, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/43910

research article

axis. Basic Res Cardiol. 2007;102(4):279–297.

  32. Rohini A, Agrawal N, Koyani CN, Singh R. Molecu-
lar targets and regulators of cardiac hypertrophy. 
Pharmacol Res. 2010;61(4):269–280.

  33. Muslin AJ. MAPK signalling in cardiovascular health 
and disease: molecular mechanisms and therapeu-
tic targets. Clin Sci (Lond). 2008;115(7):203–218.

  34. Bain J, et al. The selectivity of protein kinase inhibitors: 

a further update. Biochem J. 2007;408(3):297–315.

  35. Thompson N, Lyons J. Recent progress in target-
ing the Raf/MEK/ERK pathway with inhibitors in 
cancer drug discovery. Curr Opin Pharmacol. 2005; 
5(4):350–356.

  36. Wang JY, Wilcoxen KM, Nomoto K, Wu S. Recent 
advances of MEK inhibitors and their clinical prog-
ress. Curr Top Med Chem. 2007;7(14):1364–1378.

  37. Wentz SC, et al. Targeting MEK is effective chemopre-
vention of hepatocellular carcinoma in TGF-alpha-
transgenic mice. J Gastrointest Surg. 2008;12(1):30–37.
  38. Nakamura T, et al. Mediating ERK 1/2 signal-
ing rescues congenital heart defects in a mouse 
model of Noonan syndrome. J Clin Invest. 2007; 
117(8):2123–2132.

  39. Nakamura T, Gulick J, Colbert MC, Robbins J. Pro-
tein tyrosine phosphatase activity in the neural crest 
is essential for normal heart and skull development. 
Proc Natl Acad Sci U S A. 2009;106(27):11270–11275.
  40. Nakamura T, Gulick J, Pratt R, Robbins J. Noon-
an syndrome is associated with enhanced pERK 
activity, the repression of which can prevent cra-
niofacial malformations. Proc Natl Acad Sci U S A. 
2009;106(36):15436–15441.

  41. Araki T, et al. Mouse model of Noonan syndrome 
reveals cell type- and gene dosage-dependent effects 
of PTPN11 mutation. Nat Med. 2004;10(8):849–857.
  42. Araki T, Chan G, Newbigging S, Morikawa L, Bron-
son RT, Neel BG. Noonan syndrome cardiac defects 
are caused by PTPN11 acting in endocardium to 
enhance endocardial-mesenchymal transformation. 
Proc Natl Acad Sci U S A. 2009;106(12):4736–4741.

  43. Krenz M, Gulick J, Osinska HE, Colbert MC, Molken-
tin JD, Robbins J. Role of ERK1/2 signaling in con-

genital valve malformations in Noonan syndrome. 
Proc Natl Acad Sci U S A. 2008;105(48):18930–18935.
  44. Zhang W, et al. Negative regulation of Stat3 by activat-
ing PTPN11 mutants contributes to the pathogenesis 
of Noonan syndrome and juvenile myelomonocytic 
leukemia. J Biol Chem. 2009;284(33):22353–22363.

  45. Nimnual AS, Yatsula BA, Bar-Sagi D. Coupling of Ras 
and Rac guanosine triphosphatases through the Ras 
exchanger Sos. Science. 1998;279(5350):560–563.

  46. Innocenti M, et al. Mechanisms through which 
Sos-1 coordinates the activation of Ras and Rac.  
J Cell Biol. 2002;156(1):125–136.

  47. Gregg D, Rauscher FM, Goldschmidt-Clermont PJ. 
Rac regulates cardiovascular superoxide through 
diverse  molecular  interactions:  more  than  a 
binary GTP switch. Am J Physiol Cell Physiol. 2003; 
285(4):C723–C734.

  48. Clerk A, Sugden PH. Small guanine nucleotide-
binding proteins and myocardial hypertrophy. Circ 
Res. 2000;86(10):1019–1023.

  49. Pracyk JB, et al. A requirement for the rac1 GTPase 
in  the  signal  transduction  pathway  leading  to 
cardiac myocyte hypertrophy. J Clin Invest. 1998; 
102(5):929–937.

  50. Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiat-
kowski DJ, Liao JK. Requirement of Rac1 in the 
development of cardiac hypertrophy. Proc Natl Acad 
Sci U S A. 2006;103(19):7432–7437.

  51. Higuchi  Y,  et  al.  The  small  GTP-binding  pro-
tein Rac1 induces cardiac myocyte hypertrophy 
through the activation of apoptosis signal-regulat-
ing kinase 1 and nuclear factor-kappa B. J Biol Chem. 
2003;278(23):20770–20777.

  52. Sussman MA, et al. Altered focal adhesion regula-
tion correlates with cardiomyopathy in mice express-
ing constitutively active rac1. J Clin Invest. 2000; 
105(7):875–886.

  53. Bhat GJ, Baker KM. Cross-talk between angioten-
sin II and interleukin-6-induced signaling through 
Stat3 transcription factor. Basic Res Cardiol. 1998; 
93(suppl 3):26–29.

  54. Marrero MB, et al. Direct stimulation of Jak/STAT 

pathway by the angiotensin II AT1 receptor. Nature. 
1995;375(6528):247–250.

  55. Tsai CT, et al. Angiotensin II activates signal trans-
ducer and activators of transcription 3 via Rac1 in 
atrial myocytes and fibroblasts: implication for 
the therapeutic effect of statin in atrial structural 
remodeling. Circulation. 2008;117(3):344–355.

  56. Pan J, et al. Role of angiotensin II in activation of the 
JAK/STAT pathway induced by acute pressure over-
load in the rat heart. Circ Res. 1997;81(4):611–617.

  57. Booz GW, Day JN, Baker KM. Interplay between the 
cardiac renin angiotensin system and JAK-STAT 
signaling: role in cardiac hypertrophy, ischemia/
reperfusion dysfunction, and heart failure. J Mol 
Cell Cardiol. 2002;34(11):1443–1453.

  58. Mascareno E, Siddiqui MA. The role of Jak/STAT 
signaling in heart tissue renin–angiotensin system. 
Mol Cell Biochem. 2000;212(1–2):171–175.

  59. Haznedaroglu IC, Arici M, Buyukasik Y. A unify-
ing hypothesis for the renin-angiotensin system 
and hematopoiesis: sticking the pieces together 
with the JAK-STAT pathway. Med Hypotheses. 2000; 
 54(1):80–83.

  60. Kodama H, et al. Biphasic activation of the JAK/
STAT pathway by angiotensin II in rat cardiomyo-
cytes. Circ Res. 1998;82(2):244–250.

  61. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai 
M. Fluvastatin enhances the inhibitory effects of 
a selective angiotensin II type 1 receptor blocker, 
valsartan, on vascular neointimal formation. Circu-
lation. 2003;107(1):106–112.

  62. Simon  AR,  Vikis  HG,  Stewart  S,  Fanburg  BL, 
Cochran BH, Guan KL. Regulation of STAT3 by 
direct binding to the Rac1 GTPase. Science. 2000; 
290(5489):144–147.

  63. Pelletier S, Duhamel F, Coulombe P, Popoff MR, 
Meloche S. Rho family GTPases are required for 
activation of Jak/STAT signaling by G protein-cou-
pled receptors. Mol Cell Biol. 2003;23(4):1316–1333.
  64. Lorenz K, Schmitt JP, Vidal M, Lohse MJ. Cardiac 
hypertrophy: targeting Raf/MEK/ERK1/2-signal-
ing. Int J Biochem Cell Biol. 2009;41(12):2351–2355.

	

The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 120      Number 12      December 2010 

4365

